Kardigan Stock (NASDAQ:KARD)


FinancialsChart

Previous Close

$21.81

52W Range

$16.25 - $27.00

50D Avg

$22.09

200D Avg

$22.09

Market Cap

$1.80B

Avg Vol (3M)

$513.76K

Beta

-

Div Yield

-

KARD Company Profile


Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

241

IPO Date

Jun 18, 2026

Website

KARD Performance


KARD Financial Summary


Dec 25
Revenue-
Operating Income$-201.84M
Net Income$-191.94M
EBITDA$-195.99M
Basic EPS$-3.20
Diluted EPS$-3.20

Fiscal year ends in Dec 25 | Currency in USD